within Pharmacolibrary.Drugs.ATC.A;

model A04AD12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 62.3 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 125 / 1000000,
    adminCount     = 1,
    Vd             = 0.082,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.019666666666666666,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Aprepitant is a selective neurokinin-1 (NK1) receptor antagonist used for the prevention of acute and delayed nausea and vomiting associated with chemotherapy and for the prevention of postoperative nausea and vomiting. It is an approved, orally administered antiemetic drug.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Nijstad, AL, et al., &amp; Huitema, ADR (2023). A simple extemporaneous oral suspension of aprepitant yields sufficient pharmacokinetic exposure in children. <i>Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners</i> 29(4) 899–904. DOI:<a href=&quot;https://doi.org/10.1177/10781552221089243&quot;>10.1177/10781552221089243</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35377726/&quot;>https://pubmed.ncbi.nlm.nih.gov/35377726</a></p></li><li><p>Fujiwara, Y, et al., &amp; Minami, H (2014). Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. <i>PloS one</i> 9(8) e104215–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0104215&quot;>10.1371/journal.pone.0104215</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25121773/&quot;>https://pubmed.ncbi.nlm.nih.gov/25121773</a></p></li><li><p>Majumdar, AK, et al., &amp; Petty, KJ (2006). Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. <i>Journal of clinical pharmacology</i> 46(3) 291–300. DOI:<a href=&quot;https://doi.org/10.1177/0091270005283467&quot;>10.1177/0091270005283467</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16490805/&quot;>https://pubmed.ncbi.nlm.nih.gov/16490805</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A04AD12;
